The Economic Alliance of Greater Baltimore has received a $520,000 federal grant to bolster the state's biotechnology industry.

The Economic Alliance of Greater Baltimore (EAGB) will work with BioHealth Innovation in Montgomery County to develop a “Healthcare Regional Innovation Cluster” with the grant. The grant was awarded by the U.S. Department of Commerce’s Economic Development Administration.

WASHINGTON – U.S. Senator Barbara A. Mikulski (D-Md.), Chairwoman of the Senate Appropriations Committee, today announced that the Economic Alliance of Greater Baltimore, Inc. and BioHealth Innovation, Inc. of Montgomery County have been awarded a combined $520,000 grant through the U.S. Department of Commerce's (DOC) Economic Development Administration (EDA). The federal funding will be used to establish the Healthcare Regional Innovation Cluster (H-RIC) initiative which will combine the strengths of Maryland's cutting-edge health research institutions and unique federal assets to speed the development of new treatments and cures, supporting Maryland jobs and keeping families healthy.

This workshop on Oct 9th. had been cancelled due to the Government Shutdown and will be rescheduled at a later date.

With Fall approaching, everyone is preparing for their favorite things whether that's football season, pumpkin carving, or more reasonable temperatures in Central Maryland. Fall is also a great time for the Small Business Innovation Research grant program throughout National Institutes of Health. In partnership with the NIH, BioHealth Innovation is sponsoring a fall gathering to talk about SBIR awards.

It's useful to hear directly from NIH program officials on the current funding priorities per Institute. We have assembled program leads from NHLBI, NIAID, and NCI who can provide small businesses with more insight into their SBIR programs. They will also be available for one-on-one consultations at the conclusion of the event.

Event Details:
Wednesday, October 9th, 1:00pm – 4:00pm (EDT)
VisArts
155 Gibbs Street, 6th Floor
Rockville, MD 20850
(Overlooking Rockville Town Center)

On Wednesday August 21st, 80+ people filled the BHI parking lot for an evening of networking, eating crabs, and enjoying a relaxed, stress-free atmosphere. Represented was a who's who of the Montgomery County biohealth community and the local county government.

Thank you to everyone who made it out and we hope to see you again next time!

Through a career spanning three decades and counting, Douglas Liu has managed various operations for life sciences companies in Boston, Chicago, Europe and Montgomery County. He has been involved with numerous organizations in the field, including the Tech Council of Maryland and the Governor's International Advisory Council.

Such wide experience is a key reason he was recently chosen as board chairman of BioHealth Innovation, a Rockville-based public-private nonprofit that helps commercialize innovative ideas in the field and expand those companies. The partnership formed about two years ago after it was among the recommendations of the Montgomery County Biosciences Task Force.

BHI CEO Rich Bendis recently served as an expert panelist contributing to a special report from the "White House Lab-to-Market Inter-Agency Summit." Panelists examined the U.S. federal government's investment in drug R&D and the resulting private sector commercialization. According to the Summit report:

Federal research has done exceedingly well at accomplishing its original intent, which is to increase human knowledge, meet mission needs, and undertake high-risk research of long-term importance to the U.S. economy that is beyond the reach of the private sector. But commercialization of resulting discoveries from agency research has largely been an after-thought, despite clear Congressional and Presidential intent expressed through a series of legislative mandates and Executive Orders. While research to meet agency missions is critical, the members of the Panel believe that if the U.S. is to remain globally competitive in the 21st century, it must accelerate the translation of federally-funded R&D into commercial outcomes that create economic and public value, thus maximizing the return on the public dollars invested.

Read more at:
Increasing the Impact of Federally-Funded R&D

National Brain Tumor Society’s inaugural event draws over 100 brain tumor researchers, biopharma executives, government officials, and venture capital investors

National Brain Tumor Society, the largest nonprofit in the United States dedicated to the brain tumor community, recently hosted the inaugural Advancing Research to Therapies (ART) for Brain Tumors Conference in Washington, D.C. The ART Conference brought together more than 100 leading experts from academic research labs, government agencies, biotech and pharmaceutical companies, and venture capital firms to increase communication and collaboration, as well as discuss licensing and investment criteria for new drug candidates to speed the discovery of new treatments for brain tumor patients.

BioHealth Innovation, Inc., (BHI) a non-profit organization which strives to facilitate the development of commercially viable health IT products and companies by connecting market relevant research assets to appropriate funding, management and markets, is seeking interns as part of the BHI Internship Program.

POSITION DESCRIPTION – BHI Intern

BioHealth Innovation, Inc. (BHI), a regional private-public partnership focusing on commercializing market-relevant biohealth innovations and increasing access to early-stage funding in Central Maryland, is seeking highly motivated and dynamic individuals to fill internship positions at the Rockville, MD headquarters.  The BHI Internship Program offers essential experience for IT, Business, and Biohealth students in the region.  By offering a variety of projects and responsibilities to students, BHI aims to prepare interns for professional careers in the business, life sciences, healthcare and IT industries.

BioHealth Innovation is working to assist relevant SBIR projects through its Commercial Relevance Program for the August 5th, 2013 NIH SBIR Deadline.

If your company is planning a submission for the August 5 deadline, BioHealth Innovation can assist with your submission. Through the BHI Commercial Relevance Program for SBIR/STTR projects select companies submit their federal funding concepts and receive pre-proposal feedback to help strengthen your application. Further support from BHI’s network of professional consultants and service providers is available to assist in improving your application. If you’re are planning a submission for the August 5 deadline contact This email address is being protected from spambots. You need JavaScript enabled to view it. for details on possible support from BHI.

NIH SBIR Phase I Program

1. Companies to complete brief application describing the proposed SBIR project apply by June 18th
2. All companies notified of SBIR assistance by June 26th
3. Guidance, writing strategy, direction, and review sessions to be schedule to enable you through grant submission
4. Feedback and redlined comments on written drafts and proposals materials as well as final submission assistance